
    
      180 eligible subjects will be included.According to the set grouping method of dose
      escalation.Subjects will be randomized in a 1:1:1:1 proportion of Metacavir Enteric-coated
      Capsules(80mg/160mg/320mg) group,positive control group or placebo control group.Each group
      has 36 subjects.

      1.Subjects will use the study medication(2 hours before or after meal,once a day) from Visit
      3 to Visit 5.

        1. Metacavir Enteric-coated Capsules 80mg Group:Metacavir Enteric-coated Capsules
           80mg,Metacavir Enteric-coated Capsules Placebo 240mg,Adefovir Dipivoxil Capsule Placebo
           10mg;

        2. Metacavir Enteric-coated Capsules 160mg Group:Metacavir Enteric-coated Capsules
           160mg,Metacavir Enteric-coated Capsules Placebo 160mg,Adefovir Dipivoxil Capsule Placebo
           10mg;

        3. Metacavir Enteric-coated Capsules 320mg Group:Metacavir Enteric-coated Capsules
           320mg,Adefovir Dipivoxil Capsule Placebo 10mg;

        4. Positive Control(Adefovir Dipivoxil Capsule) Group:Metacavir Enteric-coated Capsules
           Placebo 320mg,Adefovir Dipivoxil Capsule 10mg;

        5. Placebo Control Group:Metacavir Enteric-coated Capsules Placebo 320mg,Adefovir Dipivoxil
           Capsule Placebo 10mg;
    
  